Skip to main content
OpenTrials
Recruiting

NCT Number: NCT05403177

Marathon of Hope Cancer Centres Network Study for Ontario (MOHCCN-O)

The Marathon of Hope Cancer Centres Network (MOHCCN) is a national network of cancer centres that pursue collaborative cancer research in precision medicine (an emerging approach for disease treatment and prevention that considers individual variability in DNA, environment and lifestyle) to accelerate the discovery of innovations and improve the health outcomes for cancer patients

Recruiting

Interested in participating?

Request Info

Key information

Conditions

Breast Cancer Adnexal Diseases Breast Diseases Breast Neoplasms Colonic Diseases Colorectal Cancer Colorectal Neoplasms Digestive System Diseases Digestive System Neoplasms Endocrine Gland Neoplasms Endocrine System Diseases Female Urogenital Diseases Female Urogenital Diseases and Pregnancy Complications Gastrointestinal Diseases Gastrointestinal Neoplasms Genital Diseases Genital Diseases, Female Genital Diseases, Male Genital Neoplasms, Female Genital Neoplasms, Male Gonadal Disorders Head and Neck Cancer Head and Neck Neoplasms Hematologic Diseases Hemic and Lymphatic Diseases Immune System Diseases Immunoproliferative Disorders Intestinal Diseases Intestinal Neoplasms Kidney Cancer Kidney Diseases Kidney Neoplasms Leukemia Lung Cancer Lung Diseases Lung Neoplasms Lymphatic Diseases Lymphoma Lymphoproliferative Disorders Male Urogenital Diseases Melanoma Neoplasms Neoplasms by Histologic Type Neoplasms by Site Neoplasms, Germ Cell and Embryonal Neoplasms, Nerve Tissue Neuroectodermal Tumors Neuroendocrine Tumors Nevi and Melanomas Ovarian Diseases Ovarian Neoplasms Ovary Cancer Pancreas Cancer Pancreatic Diseases Pancreatic Neoplasms Prostate Cancer Prostatic Diseases Prostatic Neoplasms Rectal Diseases Respiratory Tract Diseases Respiratory Tract Neoplasms Skin Diseases Skin Neoplasms Skin and Connective Tissue Diseases Solid Tumor Thoracic Neoplasms Urogenital Diseases Urogenital Neoplasms Urologic Diseases Urologic Neoplasms

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Kingston Health Sciences Centre, Kingston, Ontario, Canada

Loading trial locations.

About this study

The purpose of this study is to use evolving technologies such as genomics and artificial intelligence to study cancer so that the right treatment can be given to the right patient, at the right time. Approximately 15,000 participants will take part in the greater MOHCCN study across Canada in the first 5 years, and ultimately the goal is to enroll up to 100,000 over next 10 years.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patients with histological and/or cytological confirmation of blood or solid tumor malignancies. For tumour types where pre-surgical biopsy is not routinely performed to confirm a pathologic diagnosis of cancer, patients may consent to this protocol, but eligibility must be confirmed after pathology is finalized demonstrating presence of malignancy
  • All patients must be able to satisfy the required minimum data elements for the 15k gold standard cohort through:
  • Already existing data that satisfies the minimal requirements of a gold standard case (refer to Table 1)
  • Have sufficient biospecimens (tumor and/or blood samples) available for more comprehensive molecular and immunophenotypic characterization
  • Patients who do not satisfy the required minimum data elements but would like to participate, maybe requested to donate blood and undergo a fresh biopsy if the archived Formalin-fixed paraffin-embedded (FFPE) samples are not available, or in cases where a fresh tumor biopsy is deemed necessary for molecular profiling.
  • Participating patients must agree to share their anonymized clinical and genomic data

Exclusion criteria

None.

Treatment and study plan

Primary outcomes

  1. Number of patients included in a pan-Canadian cohort with comprehensive clinical and genomic data

    Time frame: 5 years

    Consolidate and annotate data from patients included in a pan-Canadian cohort

Secondary outcomes

  1. Development of standard practices to create a unique shareable dataset of molecular, imaging, clinical and health outcome information on Canadian cancer cases

    Time frame: 5 years

    Improve the cancer research paradigm by bringing teams or researchers together and leverage valuable information genomic and clinical data from Canadian cancer cases.

  2. Clinical effectiveness and cost-effectiveness of precision cancer medicine to advance clinical implementation and reimbursement decisions

    Time frame: 5 years

    Health technology assessment tools will be used to evaluate the real-world value of precision medicine

  3. Development and collection of patient-reported outcomes to enhance patient-centeredness in precision cancer medicine

    Time frame: 5 years

    Health technology assessment tools will be used to evaluate the real-world value of precision medicine

Study contacts

Contact information is provided by the study sponsor or research team.

PM2C Central Office

CONTACT

[email protected]

416-946-4501 ext. 3486

Sponsors and collaborators

Lead sponsor

University Health Network, Toronto

Other

Collaborators

  • Kingston Health Sciences Centre
  • London Health Sciences Centre
  • London Health Sciences Centre Research Institute
  • Ontario Institute for Cancer Research
  • Ottawa Hospital Research Institute
  • Princess Margaret Hospital, Canada
  • Queen's University, Kingston, Ontario
  • Terry Fox Research Institute
  • University of Windsor
  • Windsor Regional Hospital

Registry information

Acronym: MOHCCN-O

Important dates

Study start
2022
Primary completion
2030
Study completion
2030
First posted
Jun 3, 2022
Registry last updated
Jun 10, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.